Stock Name: Biosensors
Company Name: BIOSENSORS INT'L GROUP, LTD.
Research House: OCBC
OCBC says the results were strong, with revenue within expectation, core earnings slightly higher than forecast. The house notes good gross profit, EBIT margins, at 77.7% (vs 72.4% in 3Q10, 78.7% in 2Q11) and 30.6% (vs 24.1% in 3Q10, 25.8% in 2Q11) respectively: “This was due largely to improving manufacturing efficiency, change in product mix and lower expenses resulting from its U.S. restructuring exercise.”
Company Name: BIOSENSORS INT'L GROUP, LTD.
Research House: OCBC
Biosensors (B20.SG) off 1.8% at $1.12, falling along with the broad market despite posting yearly and sequential gains in earnings. 3Q revenue rose 31.8% on-year, 16.8% on-quarter to US$42.6 million ($54.8 million), net profit rose 7.8% on-year, and climbed 57.6% on-quarter to US$13.3 million.
OCBC says the results were strong, with revenue within expectation, core earnings slightly higher than forecast. The house notes good gross profit, EBIT margins, at 77.7% (vs 72.4% in 3Q10, 78.7% in 2Q11) and 30.6% (vs 24.1% in 3Q10, 25.8% in 2Q11) respectively: “This was due largely to improving manufacturing efficiency, change in product mix and lower expenses resulting from its U.S. restructuring exercise.”
The house adds that drug-eluting stents continue to be the key growth driver, with the segment’s sales rising 60.0% on-year, “which helped to offset a decline in sales of other interventional cardiology products.”
OCBC keeps its Buy rating and nudges its target to $1.36 from to $1.35; “We remain sanguine about BIG’s growth prospects.”
No comments:
Post a Comment